New shot aims to tame severe skin itch and rash
NCT ID NCT07399067
Summary
This study is testing whether a new injectable drug called IBI3002 can safely reduce the itchy rash and inflammation of moderate-to-severe eczema (atopic dermatitis). About 120 adults with long-term eczema will receive injections of IBI3002, an approved drug (dupilumab), or a placebo for 16 weeks to see which works best. The main goal is to see how much the drug can improve skin symptoms and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100192, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.